Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Vaccination of guinea pigs with BCGΔBCG1419c transiently reduces hematogenous spread of M. tuberculosis to the spleen.

Aceves-Sánchez MJ, Flores-Valdez MA, Shanley C, Orme I, Bielefeldt-Ohmann H.

Pathog Dis. 2018 Dec 1;76(9). doi: 10.1093/femspd/fty088.

PMID:
30500936
2.

Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to Mycobacterium tuberculosis.

Orme IM, Henao-Tamayo MI.

Front Immunol. 2018 Mar 8;9:461. doi: 10.3389/fimmu.2018.00461. eCollection 2018. Review.

3.

Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission.

Shanley CA, Henao-Tamayo MI, Bipin C, Mugasimangalam R, Verma D, Ordway DJ, Streicher EM, Orme IM.

Tuberculosis (Edinb). 2018 Mar;109:123-133. doi: 10.1016/j.tube.2018.02.003. Epub 2018 Feb 9.

4.

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

King TH, Shanley CA, Guo Z, Bellgrau D, Rodell T, Furney S, Henao-Tamayo M, Orme IM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00245-17. doi: 10.1128/CVI.00245-17. Print 2017 Dec.

6.

Animal Models of Tuberculosis: An Overview.

Williams A, Orme IM.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.TBTB2-0004-2015. Review.

PMID:
27726810
7.

Mouse and Guinea Pig Models of Tuberculosis.

Orme IM, Ordway DJ.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.TBTB2-0002-2015. Review.

PMID:
27726797
8.

Effect of bacillus Calmette-Guérin vaccination on CD4+Foxp3+ T cells during acquired immune response to Mycobacterium tuberculosis infection.

Henao-Tamayo MI, Obregón-Henao A, Arnett K, Shanley CA, Podell B, Orme IM, Ordway DJ.

J Leukoc Biol. 2016 Apr;99(4):605-17. doi: 10.1189/jlb.4A0614-308RR. Epub 2015 Nov 20.

9.

The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis.

Henao-Tamayo M, Shanley CA, Verma D, Zilavy A, Stapleton MC, Furney SK, Podell B, Orme IM.

PLoS One. 2015 Sep 14;10(9):e0136500. doi: 10.1371/journal.pone.0136500. eCollection 2015.

10.

Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.

Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, Takeda K, Chan MM, Dakhama A, Kinney WH, Trostel J, Bai A, Honda JR, Achcar R, Hartney J, Joosten LA, Kim SH, Orme I, Dinarello CA, Ordway DJ, Chan ED.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5111-6. doi: 10.1073/pnas.1424302112. Epub 2015 Mar 27.

11.

The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression.

Robinson RT, Orme IM, Cooper AM.

Immunol Rev. 2015 Mar;264(1):46-59. doi: 10.1111/imr.12259. Review.

PMID:
25703551
12.

A new antibiotic with potent activity targets MscL.

Iscla I, Wray R, Blount P, Larkins-Ford J, Conery AL, Ausubel FM, Ramu S, Kavanagh A, Huang JX, Blaskovich MA, Cooper MA, Obregon-Henao A, Orme I, Tjandra ES, Stroeher UH, Brown MH, Macardle C, van Holst N, Ling Tong C, Slattery AD, Gibson CT, Raston CL, Boulos RA.

J Antibiot (Tokyo). 2015 Jul;68(7):453-62. doi: 10.1038/ja.2015.4. Epub 2015 Feb 4.

13.

Whole genome response in guinea pigs infected with the high virulence strain Mycobacterium tuberculosis TT372.

Aiyaz M, Bipin C, Pantulwar V, Mugasimangalam R, Shanley CA, Ordway DJ, Orme IM.

Tuberculosis (Edinb). 2014 Dec;94(6):606-15.

14.

Tuberculosis vaccine types and timings.

Orme IM.

Clin Vaccine Immunol. 2015 Mar;22(3):249-57. doi: 10.1128/CVI.00718-14. Epub 2014 Dec 24. Review.

15.

The balance between protective and pathogenic immune responses in the TB-infected lung.

Orme IM, Robinson RT, Cooper AM.

Nat Immunol. 2015 Jan;16(1):57-63. doi: 10.1038/ni.3048. Review.

PMID:
25521685
16.

Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects.

Orme IM.

Tuberculosis (Edinb). 2016 Dec;101:210-216. doi: 10.1016/j.tube.2014.10.008. Epub 2014 Nov 27. Review.

PMID:
25500316
17.

The formation of the granuloma in tuberculosis infection.

Orme IM, Basaraba RJ.

Semin Immunol. 2014 Dec;26(6):601-9. doi: 10.1016/j.smim.2014.09.009. Epub 2014 Oct 22. Review.

PMID:
25453231
18.

bis-Molybdopterin guanine dinucleotide is required for persistence of Mycobacterium tuberculosis in guinea pigs.

Williams MJ, Shanley CA, Zilavy A, Peixoto B, Manca C, Kaplan G, Orme IM, Mizrahi V, Kana BD.

Infect Immun. 2015 Feb;83(2):544-50. doi: 10.1128/IAI.02722-14. Epub 2014 Nov 17.

19.

Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.

Henao-Tamayo M, Obregón-Henao A, Creissen E, Shanley C, Orme I, Ordway DJ.

Clin Vaccine Immunol. 2015 Jan;22(1):91-8. doi: 10.1128/CVI.00466-14. Epub 2014 Nov 12.

20.

Letter to the editor.

Orme I.

Tuberculosis (Edinb). 2014 Dec;94(6):717. doi: 10.1016/j.tube.2014.08.004. Epub 2014 Sep 19. No abstract available.

PMID:
25293999
21.

The endothelin system has a significant role in the pathogenesis and progression of Mycobacterium tuberculosis infection.

Correa AF, Bailão AM, Bastos IM, Orme IM, Soares CM, Kipnis A, Santana JM, Junqueira-Kipnis AP.

Infect Immun. 2014 Dec;82(12):5154-65. doi: 10.1128/IAI.02304-14. Epub 2014 Sep 29.

22.

Memory T cell subsets in tuberculosis: what should we be targeting?

Henao-Tamayo M, Ordway DJ, Orme IM.

Tuberculosis (Edinb). 2014 Sep;94(5):455-61. doi: 10.1016/j.tube.2014.05.001. Epub 2014 Jun 17. Review.

PMID:
24993316
23.

Host response to nontuberculous mycobacterial infections of current clinical importance.

Orme IM, Ordway DJ.

Infect Immun. 2014 Sep;82(9):3516-22. doi: 10.1128/IAI.01606-13. Epub 2014 Jun 9.

24.

Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity.

Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M, Orme IM, Ordway DJ, Basaraba RJ.

Am J Pathol. 2014 Apr;184(4):1104-1118. doi: 10.1016/j.ajpath.2013.12.015. Epub 2014 Jan 31.

25.

Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis.

Ackart DF, Hascall-Dove L, Caceres SM, Kirk NM, Podell BK, Melander C, Orme IM, Leid JG, Nick JA, Basaraba RJ.

Pathog Dis. 2014 Apr;70(3):359-69. doi: 10.1111/2049-632X.12144. Epub 2014 Feb 24.

26.

Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2014 Mar;94(2):140-7. doi: 10.1016/j.tube.2013.08.010. Epub 2013 Sep 7.

27.

Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection.

Obregón-Henao A, Henao-Tamayo M, Orme IM, Ordway DJ.

PLoS One. 2013 Nov 1;8(11):e80669. doi: 10.1371/journal.pone.0080669. eCollection 2013.

28.

A new unifying theory of the pathogenesis of tuberculosis.

Orme IM.

Tuberculosis (Edinb). 2014 Jan;94(1):8-14. doi: 10.1016/j.tube.2013.07.004. Epub 2013 Aug 4.

29.

Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape.

Shanley CA, Streicher EM, Warren RM, Victor TC, Orme IM.

Vaccine. 2013 Dec 5;31(50):5934-9. doi: 10.1016/j.vaccine.2013.10.044. Epub 2013 Oct 19.

30.

Mycobacterium tuberculosis nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity.

Sun J, Singh V, Lau A, Stokes RW, Obregón-Henao A, Orme IM, Wong D, Av-Gay Y, Hmama Z.

PLoS Pathog. 2013;9(7):e1003499. doi: 10.1371/journal.ppat.1003499. Epub 2013 Jul 18.

31.

Vaccine development for tuberculosis: current progress.

Orme IM.

Drugs. 2013 Jul;73(10):1015-24. doi: 10.1007/s40265-013-0081-8. Review.

32.

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ.

Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30. Review.

33.

Metabolomic signatures in guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis.

Somashekar BS, Amin AG, Tripathi P, MacKinnon N, Rithner CD, Shanley CA, Basaraba R, Henao-Tamayo M, Kato-Maeda M, Ramamoorthy A, Orme IM, Ordway DJ, Chatterjee D.

J Proteome Res. 2012 Oct 5;11(10):4873-84. doi: 10.1021/pr300345x. Epub 2012 Aug 30.

PMID:
22873951
34.

Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig.

Kato-Maeda M, Shanley CA, Ackart D, Jarlsberg LG, Shang S, Obregon-Henao A, Harton M, Basaraba RJ, Henao-Tamayo M, Barrozo JC, Rose J, Kawamura LM, Coscolla M, Fofanov VY, Koshinsky H, Gagneux S, Hopewell PC, Ordway DJ, Orme IM.

Clin Vaccine Immunol. 2012 Aug;19(8):1227-37. doi: 10.1128/CVI.00250-12. Epub 2012 Jun 20.

35.

Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infection in guinea pigs.

Palanisamy GS, Kirk NM, Ackart DF, Obregón-Henao A, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2012;7(3):e34148. doi: 10.1371/journal.pone.0034148. Epub 2012 Mar 30.

36.

A mouse model of tuberculosis reinfection.

Henao-Tamayo M, Obregón-Henao A, Ordway DJ, Shang S, Duncan CG, Orme IM.

Tuberculosis (Edinb). 2012 May;92(3):211-7. doi: 10.1016/j.tube.2012.02.008. Epub 2012 Mar 17.

PMID:
22429719
37.

BCG: myths, realities, and the need for alternative vaccine strategies.

McShane H, Jacobs WR, Fine PE, Reed SG, McMurray DN, Behr M, Williams A, Orme IM.

Tuberculosis (Edinb). 2012 May;92(3):283-8. doi: 10.1016/j.tube.2011.12.003. Epub 2012 Feb 18. No abstract available.

38.

Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, Ackart D, Orme IM, Ordway DJ, Basaraba RJ.

Vaccine. 2012 Feb 21;30(9):1572-82. doi: 10.1016/j.vaccine.2011.12.114. Epub 2012 Jan 11.

39.

Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

De Groote MA, Gruppo V, Woolhiser LK, Orme IM, Gilliland JC, Lenaerts AJ.

Antimicrob Agents Chemother. 2012 Feb;56(2):731-8. doi: 10.1128/AAC.05701-11. Epub 2011 Dec 5.

40.

Immune Responses of HIV-1 Tat Transgenic Mice to Mycobacterium Tuberculosis W-Beijing SA161.

Honda JR, Shang S, Shanley CA, Caraway ML, Henao-Tamayo M, Chan ED, Basaraba RJ, Orme IM, Ordway DJ, Flores SC.

Open AIDS J. 2011;5:86-95. doi: 10.2174/1874613601105010086. Epub 2011 Oct 19.

41.

Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis.

Palanisamy GS, Kirk NM, Ackart DF, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2011;6(10):e26254. doi: 10.1371/journal.pone.0026254. Epub 2011 Oct 18.

42.

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.

Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo M, Ordway D, Sellers RS, Jain P, Chen B, Chen M, Kim J, Lukose R, Chan J, Orme IM, Porcelli SA, Jacobs WR Jr.

Nat Med. 2011 Sep 4;17(10):1261-8. doi: 10.1038/nm.2420.

43.

Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Ching LK, Mompoint F, Guderian JA, Picone A, Orme IM, Coler RN, Reed SG, Baldwin SL.

J Immunol Methods. 2011 Oct 28;373(1-2):54-62. doi: 10.1016/j.jim.2011.07.021. Epub 2011 Aug 3.

44.

Animal models of mycobacteria infection.

Ordway DJ, Orme IM.

Curr Protoc Immunol. 2011 Aug;Chapter 19:Unit19.5. doi: 10.1002/0471142735.im1905s94.

PMID:
21809318
45.

Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Ordway DJ, Shang S, Henao-Tamayo M, Obregon-Henao A, Nold L, Caraway M, Shanley CA, Basaraba RJ, Duncan CG, Orme IM.

Clin Vaccine Immunol. 2011 Sep;18(9):1527-35. doi: 10.1128/CVI.05127-11. Epub 2011 Jul 27.

46.

Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis.

Shang S, Harton M, Tamayo MH, Shanley C, Palanisamy GS, Caraway M, Chan ED, Basaraba RJ, Orme IM, Ordway DJ.

Tuberculosis (Edinb). 2011 Sep;91(5):378-85. doi: 10.1016/j.tube.2011.06.001. Epub 2011 Jul 6.

47.

T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis.

Henao-Tamayo M, Irwin SM, Shang S, Ordway D, Orme IM.

Tuberculosis (Edinb). 2011 Jul;91(4):308-13. doi: 10.1016/j.tube.2011.04.001. Epub 2011 Apr 29.

48.

Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Obregón-Henao A, Shanley C, Bianco MV, Cataldi AA, Basaraba RJ, Orme IM, Bigi F.

Vaccine. 2011 Jun 10;29(26):4302-7. doi: 10.1016/j.vaccine.2011.04.027. Epub 2011 Apr 22.

49.

Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis.

Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, Weyer K, Mphahlele M, Venter K, Jensen PA, First MW, Parsons S, McMurray DN, Orme IM, Nardell EA.

Tuberculosis (Edinb). 2011 Jul;91(4):329-38. doi: 10.1016/j.tube.2011.03.002. Epub 2011 Apr 7.

50.

Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Orme IM.

Future Microbiol. 2011 Feb;6(2):161-77. doi: 10.2217/fmb.10.168. Review.

Supplemental Content

Support Center